| Lymphoma, Follicular
Lunsumio vs Zevalin
Side-by-side clinical, coverage, and cost comparison for lymphoma, follicular.Deep comparison between: Lunsumio vs Zevalin with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZevalin has a higher rate of injection site reactions vs Lunsumio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zevalin but not Lunsumio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Lunsumio
Zevalin
At A Glance
IV infusion
Every 3 weeks
Bispecific CD20xCD3 T-cell engager
IV infusion
Single course
CD20-directed radioimmunotherapy
Indications
- Lymphoma, Follicular
- Lymphoma, Follicular
Dosing
Lymphoma, Follicular Step-up dosing: 1 mg IV (Cycle 1 Day 1), 2 mg (Cycle 1 Day 8), 60 mg (Cycle 1 Day 15), 60 mg (Cycle 2 Day 1), then 30 mg every 3 weeks (Cycles 3+); 21-day cycles; administer as IV infusion over a minimum of 4 hours for initial doses.
Lymphoma, Follicular Day 1: rituximab 250 mg/m2 IV; Day 7, 8, or 9: rituximab 250 mg/m2 IV then Y-90 Zevalin 0.4 mCi/kg IV over 10 minutes (platelets >=150,000/mm3) or 0.3 mCi/kg IV over 10 minutes (platelets 100,000-149,000/mm3, relapsed or refractory); maximum dose 32 mCi; single course.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) CRS, fatigue, rash, pyrexia, headache, musculoskeletal pain, cough, pruritus, peripheral neuropathy, edema, diarrhea, nausea, dry skin, upper respiratory tract infection, chills, dizziness, insomnia, abdominal pain, arthralgia, dyspnea, skin exfoliation, urinary tract infection
Serious CRS, infections (sepsis, pneumonia, urinary tract infection, EBV viremia, COVID-19, upper respiratory tract infection), renal insufficiency, pyrexia, tumor flare
Most common (>=5%) Cytopenias (thrombocytopenia, neutropenia, anemia, leukopenia, lymphopenia), fatigue, nasopharyngitis, nausea, abdominal pain, asthenia, cough, diarrhea, pyrexia
Serious Prolonged and severe cytopenias (thrombocytopenia, anemia, lymphopenia, neutropenia), MDS/AML, serious infusion reactions, severe cutaneous and mucocutaneous reactions
Postmarketing Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous dermatitis, exfoliative dermatitis, infusion site erythema and ulceration, radiation injury
Pharmacology
Mosunetuzumab-axgb is a bispecific CD20-directed CD3 T-cell engaging antibody that binds CD3 on T-cells and CD20 on lymphoma and B-lineage cells, activating T-cells to induce B-cell lysis and cytokine release.
Ibritumomab tiuxetan is a murine IgG1 kappa monoclonal antibody immunoconjugate that binds specifically to the CD20 antigen on pre-B and mature B lymphocytes and >90% of B-cell NHL; the covalently linked Y-90 chelate (tiuxetan) delivers targeted beta radiation, inducing cellular damage via free radical formation in CD20-expressing and neighboring cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Lunsumio
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
No coverage data available for Zevalin.
UnitedHealthcare
Lunsumio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
No coverage data available for Zevalin.
Humana
Lunsumio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
No coverage data available for Zevalin.
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LunsumioView full Lunsumio profile
ZevalinView full Zevalin profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.